The association between COVID-19, neurotrophic factor reduction, and microglia activation emphasizes continuing research in exploring other therapeutic options aimed at moderating microglia overactivation, restoring NGF and BDNF presence, and decreasing inflammation. The gene discussed is BDNF; the disease is COVID-19.